RxDoctor Payments Data

Alyssa Becker, MD

Internal Medicine · Saddle River, NJNPI 1023187143

Payments from drug & device makers

$5,719in general payments, 2019–2025

Across 274 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$937
  • Lilly USA, LLC$686
  • Amgen$584
  • Boehringer Ingelheim$507
  • Daiichi Sankyo Inc.$147
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$5,719100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,719 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$78,069
Medicare patients
227
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$81,690
OzempicSemaglutide32$33,168
RybelsusSemaglutide13$24,764
JanuviaSitagliptin Phosphate28$24,607
EliquisApixaban14$18,138
LinzessLinaclotide16$13,729
Atorvastatin Calcium180$2,112
Levothyroxine Sodium163$2,053
Metoprolol Succinate88$1,577
Rosuvastatin Calcium87$1,500
Losartan Potassium103$1,238
SynthroidLevothyroxine Sodium11$1,230
Amlodipine Besylate154$1,133
Omeprazole54$812
Metformin Hcl101$784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$507$81,69067 claims
Novo NordiskOzempic, Rybelsus$1,553$57,93345 claims
MerckJanuvia$13$24,60728 claims
PfizerEliquis$75$18,13814 claims
AbbVieLinzess, Synthroid$937$14,95927 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$2,053163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Saddle River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →